SPPI Spectrum Pharmaceuticals, Inc.

6.97
+0  (8%)
Previous Close 6.48
Open 6.50
Price To book 2.15
Market Cap 545.85M
Shares 78,314,000
Volume 1,744,833
Short Ratio 7.08
Av. Daily Volume 766,668

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation announced March 30, 2017 with preliminary data due by the end of 2017.
Poziotinib
Non-small cell lung cancer (NSCLC)
CRL received October 9, 2009. Approved April 29, 2011.
FUSILEV
Colorectal cancer
CRL received July 5, 2009.
ZEVALIN
Non-Hodgkin’s lymphoma
CRL October 23 2015. Approved March 15 2016.
EVOMELA (melphalan) for Injection
Conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma
Phase 2 initiated March 2016. Data due by the end of 2017.
Poziotinib
Breast cancer
Failed to meet primary endpoint in Phase 3 trial - Apr 2012. PDUFA date December 11 2016. Advisory Committee Meeting September 14 2016 voted 14 - 0 against approval. CRL issued November 17, 2016. Comapny has received a new SPA from the FDA on a new Phase 3 study design.
QAPZOLA - Apaziquone
Bladder cancer
Phase 3 trial began enrollment January 2016. BLA filing due 2018.
SPI-2012 (ROLONTIS)
Chemotherapy-Induced Neutropenia
Approved July 7, 2014.
Belinostat
Peripheral T-Cell Lymphoma cancer

Latest News

  1. Today's Research Reports on Biotech Stocks to Watch: Celldex Therapeutics and Spectrum Pharmaceuticals
  2. Spectrum Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SPPI-US : April 14, 2017
  3. ETFs with exposure to Spectrum Pharmaceuticals, Inc. : April 7, 2017
  4. Spectrum Pharmaceuticals Highlights Preclinical Data of ROLONTIS™ (eflapegrastim) at the American Association for Cancer Research (AACR) Annual Meeting
  5. Spectrum (SPPI) Initiates Phase II Study for Cancer Candidate
  6. Spectrum Pharmaceuticals Highlights Three Abstracts on ROLONTIS™ (eflapegrastim) and BELEODAQ® (belinostat) for injection at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C., April 1-5, 2017
  7. Spectrum Pharmaceuticals Announces Initiation of a Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
  8. Spectrum Pharmaceuticals, Inc. :SPPI-US: Earnings Analysis: Q4, 2016 By the Numbers : March 9, 2017
  9. Biotech Premarket Movers: Spectrum, BioCryst, Curis
  10. Spectrum (SPPI) Q4 Loss Narrower than Expected, Sales Beat
  11. Spectrum Pharma reports 4Q loss
  12. Spectrum Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results and Pipeline Update
  13. Should You Buy Spectrum Pharmaceuticals (SPPI) Ahead of Earnings?
  14. Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results Teleconference and Webcast
  15. Spectrum Pharma Sued Again For 'Misleading Investors’
  16. Top 4 Small-Cap Stocks for 2017
  17. Spectrum Pharmaceuticals to Present Corporate Update at the 2017 RBC Capital Markets Global Healthcare Conference on February 23rd
  18. ETFs with exposure to Spectrum Pharmaceuticals, Inc. : January 20, 2017
  19. Is Steel Partners Holdings LP (SPLP) A Good Stock To Buy According To Other Hedge Funds?
  20. ETFs with exposure to Spectrum Pharmaceuticals, Inc. : December 14, 2016